van den Bosch Annemien E, Ruys Titia P E, Roos-Hesselink Jolien W
Department of Cardiology, Thorax Center, Erasmus Medical Center, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Future Cardiol. 2015;11(1):89-100. doi: 10.2217/fca.14.68.
Cardiovascular disease is the most encountered cause of maternal death during pregnancy in the western world and an increase in maternal mortality due to cardiac causes has been observed. More women with congenital or acquired heart disease have the desire to become pregnant. Pregnancy is known to impose a major hemodynamic burden and also has impacts on the coagulation system. The risk of developing complications is clearly increased as compared with the normal population. For optimal management, it is crucial to have information on the effects of cardiac medications on the fetus. The focus of this article is to discuss the management of cardiac disease in pregnancy, as well as the known safety of cardiac medications for the mother and/or fetus.
在西方世界，心血管疾病是孕期孕产妇死亡最常见的原因，且已观察到因心脏原因导致的孕产妇死亡率有所上升。越来越多患有先天性或后天性心脏病的女性有怀孕的意愿。众所周知，怀孕会带来巨大的血流动力学负担，并且对凝血系统也有影响。与正常人群相比，出现并发症的风险明显增加。为了进行最佳管理，了解心脏药物对胎儿的影响至关重要。本文的重点是讨论孕期心脏病的管理以及心脏药物对母亲和/或胎儿的已知安全性。
